US4508727A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antihypertensive 2-oxo-imidazolidine derivatives
Assignee: Tanabe Pharma Corp
•
Filing: 1983-05-24
•
Granted: 1985-04-02
•
Expires: 2003-05-24
Abstract
Abstract Novel 2-oxo-imidazolidine derivative of the formula: <IMAGE> (I) wherein R1 is lower alkyl or phenyl-lower alkyl, R2 is lower alkyl, R3 is alkyl of one to 12 carbon atoms or phenyl-lower alkyl and R4 is hydrogen or lower alkyl, and a pharmaceutically acceptable salts thereof are disclsoed. Said compounds (I) and salts thereof are useful as hypotensive agents.
Inventors
- 👤 Naoto Yoneda
- 👤 Jyoji Kato
- 👤 Kimiaki Hayashi
- 👤 Takashi Ochiai
- 👤 Keizo Kinashi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 16:12
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/02; C07K5/022; C07K5/0222; A; A61; A61P; A61P35/00; A61P43/00; A61P9/00; A61P9/12; C07D; C07D233/00; C07D233/04; C07D233/28; C07D233/30; C07D233/32; A61K; A61K38/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
18 words
A compound of the formula: ##STR9## wherein R 4 is lower alkyl, or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
18 words
A compound of the formula: ##STR9## wherein R 4 is lower alkyl, or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
16 words
The compound claimed in claim 1 which is 1-methyl-3-{2-[N-(1-ethoxycarbonyl-3-phenylpropyl)amino]propionyl}-2-oxo-imidazolidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
16 words
The compound claimed in claim 1 which is (4S)-1-methyl-3-{(2S)-2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl)amino]propionyl}-2-oxo-imidazolidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
36 words
A hypotensive pharmaceutical composition which comprises a therapeutically effective amount of an active compound of the formula: ##STR10## wherein R 4 is lower alkyl, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.
Claim 6
Dependent Claim
36 words
A hypotensive pharmaceutical composition which comprises a therapeutically effective amount of an active compound of the formula: ##STR10## wherein R 4 is lower alkyl, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.
Claim 7
Dependent Claim
20 words
The hypotensive pharmaceutical composition of claim 4, wherein said active compound is 1-methyl-3-{2-[N-(1-ethoxycarbonyl-3-phenylpropyl)amino]-propionyl}-2-oxo-imidazolidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
20 words
The hypotensive pharmaceutical compositon of claim 4, wherein said active compound is (4S)-1-methyl-3-{2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl)amino]propiopyl}-2-oxo-imidazolidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof.
Claim 9
Independent Claim
39 words
A method of producing a hypotensive effect on a warm-blooded animal comprising administering to said warm-blooded animal an effective amount of a compound of the formula: ##STR11## wherein R 4 is lower alkyl, or a pharmaceutically acceptable salt thereof.
Claim 10
Independent Claim
39 words
A method of producing a hypotensive effect on a warm-blooded animal comprising administering to said warm-blooded animal an effective amount of a compound of the formula: ##STR11## wherein R 4 is lower alkyl, or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
28 words
The method of producing a hypotensive effect on a warm-blooded animal, in accordance with claim 7, wherein said compound is 1-methyl-3-{2-[N-(1-ethoxycarbonyl-3-phenylpropyl)amino]propionyl}-2-oxo-imidazolidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim
28 words
The method of producing a hypotensive effect on a warm-blooded animal, in accordance with claim 7, wherein said compound is (4s)-1-methyl-3-{(2S)-2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl)amino]propionyl}-2-oxo-imidazolidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
EP0012401A1
Cited
US4374829A
Cited
EP0048159A2
Cited
EP0050866A1
Cited
US4380644A
Cited
JPS5835114A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-04-01 | 1988-10-01 | 1989-04-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-04-01 | 1992-10-01 | 1993-04-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-04-01 | 1996-10-01 | 1997-04-02 | $7700.00 | Window Closed / Lapsed |